The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Axon degeneration in Parkinson's disease
Open accessAbstract
Parkinson's disease (PD) is the most common neurodegenerative disease of the basal ganglia. Like other adult-onset neurodegenerative disorders, it is without a treatment that forestalls its chronic progression. Efforts to develop disease-modifying therapies to date have largely focused on the prevention of degeneration of the neuron soma, with the tacit assumption that such approaches will forestall axon degeneration as well. We herein propose that future efforts to develop neuroprotection for PD may benefit from a shift in focus to the distinct mechanisms that underlie axon degeneration. We review evidence from human post-mortem studies, functional neuroimaging, genetic causes of the disease and neurotoxin models that axon degeneration may be the earliest feature of the disease, and it may therefore be the most appropriate target for early intervention. In addition, we present evidence that the molecular mechanisms of degeneration of axons are separate and distinct from those of neuron soma. Progress is being made in understanding these mechanisms, and they provide possible new targets for therapeutic intervention. We also suggest that the potential for axon re-growth in the adult central nervous system has perhaps been underestimated, and it offers new avenues for neurorestoration. In conclusion, we propose that a new focus on the neurobiology of axons, their molecular pathways of degeneration and growth, will offer novel opportunities for neuroprotection and restoration in the treatment of PD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“However, this debate has centered around regional studies of α-synuclein pathology in the post-mortem brain (Braak et al., 2003).”
BackgroundSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 1×
“LBs contain a variety of cellular proteins, the most abundant being α-synuclein (Spillantini et al., 1997) a protein that normally is abundant in nerve terminals (Iwai et al., 1995, Maroteaux et al., 1988).”
BackgroundMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 3×
“Since the discovery of disease-causing mutations in α-synuclein in 1997 (Polymeropoulos et al., 1997), subsequent discoveries of other genetic causes of PD have had a major impact on current research on pathogenesis.”
BackgroundDauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“, 2004), which, like α-synuclein, causes an autosomal dominant form of PD, and mutations in parkin (Kitada et al., 1998), DJ-1 (Bonifati et al.”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway
Park, K. K., Liu, K., Hu, Y., Smith, P. D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I., Sahin, M., et al. (2008) · Science · doi:10.1126/science.1161566 · Cited by 1,686
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal
Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,641
Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., & Lee, V. M.-Y. (2011) · Neuron · doi:10.1016/j.neuron.2011.08.033 · Cited by 1,569
Immunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316
Mechanism of Toxicity in Rotenone Models of Parkinson's Disease
Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., & Greenamyre, J. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10756.2003 · Cited by 1,072
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 2×
“(Figure modified from (Cheng et al., 2010)).”
BackgroundSelf-citationTRANSPLANTATION OF EMBRYONIC DOPAMINE NEURONS FOR SEVERE PARKINSON'S DISEASE
Reed, R., Reene, P. A. E. G., Reeze, R. O. E. B., Ei, W., Ouchel, W. I. D. U. M., Ao, R. I. K., Infield, W., Ulver, S. H. C., Rojanowski, J. O. Q. T., Idelberg, D. A. E., et al. (2001) · Cited by 1,001
PTEN deletion enhances the regenerative ability of adult corticospinal neurons
Liu, K., Lu, Y., Lee, J. K., Samara, R., Willenberg, R., Sears-Kraxberger, I., Tedeschi, A., Park, K. K., Jin, D., Cai, B., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2603 · Cited by 985
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801 · cited 2×
“, 2004), all of which cause autosomal recessive forms of the disorder (reviewed in (Shulman et al., 2011)).”
BackgroundThe Interplay Between Mitochondrial Dynamics and Mitophagy
Twig, G., & Shirihai, O. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3779 · Cited by 778
A complex interplay between Akt, TSC2 and the two mTOR complexes
Huang, J., & Manning, B. D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370217 · Cited by 724 · cited 1×
“This inhibition relieves suppression of the GTPase Rheb, which in turn activates the mTORC1 kinase, a negative regulator of autophagy (Foster and Fingar, 2010, Huang and Manning, 2009, Laplante and Sabatini, 2009).”
BackgroundAbsence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646 · cited 1×
“This mutation arose spontaneously in C57Bl/6 mice, and it was demonstrated to cause delayed Wallerian degeneration in peripheral nerve after axotomy (Lunn et al., 1989).”
BackgroundAxonal Self-Destruction and Neurodegeneration
Raff, M. C., Whitmore, A. V., & Finn, J. T. (2002) · Science · doi:10.1126/science.1068613 · Cited by 640
(2004) · doi:10.1002/ana.10846 · Cited by 614
Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
Riederer, P., & Wuketich, S. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249445 · Cited by 577
Kramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Biochemical aspects of Parkinson's disease
Hornykiewicz, O. (1998) · Neurology · doi:10.1212/wnl.51.2_suppl_2.s2 · Cited by 564
The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology
MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., & Abeliovich, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.008 · Cited by 564
Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease
Li, Y., Liu, W., Oo, T. F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2349 · Cited by 536
Self-citationMammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses
Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E., & Ikuta, F. (1988) · Acta Neuropathologica · doi:10.1007/bf00687767 · Cited by 528
Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells
Plowey, E. D., Cherra, S. J., Liu, Y., & Chu, C. T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05217.x · Cited by 493
Shults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
Wallerian Degeneration, WldS, and Nmnat
Coleman, M. P., & Freeman, M. R. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153248 · Cited by 473
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070209 · Cited by 472
Orimo, S., Uchihara, T., Nakamura, A., Mori, F., Kakita, A., Wakabayashi, K., & Takahashi, H. (2008) · Brain · doi:10.1093/brain/awm302 · Cited by 462
Galvin, J. E., Uryu, K., Lee, V. M.-Y., & Trojanowski, J. Q. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13450 · Cited by 422
Pakkenberg, B., Moller, A., Gundersen, H. J., Mouritzen Dam, A., & Pakkenberg, H. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.1.30 · Cited by 407
Neuropathology of Autonomic Nervous System in Parkinson's Disease
Wakabayashi, K., & Takahashi, H. (1997) · European Neurology · doi:10.1159/000113469 · Cited by 407
Axon pathology in neurological disease: a neglected therapeutic target
Coleman, M. P., & Perry, V. H. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02255-5 · Cited by 389
A critical evaluation of the Braak staging scheme for Parkinson's disease
Burke, R. E., Dauer, W. T., & Vonsattel, J. P. G. (2008) · Annals of Neurology · doi:10.1002/ana.21541 · Cited by 377
Self-citationMarsden, C. D. (1990) · The Lancet · doi:10.1016/0140-6736(90)91006-v · Cited by 357
Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J.-Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J.-J., & Duyckaerts, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 354
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Larsen, K. E., Fon, E. A., Hastings, T. G., Edwards, R. H., & Sulzer, D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08951.2002 · Cited by 335
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases
Duda, J. E., Giasson, B. I., Mabon, M. E., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · Annals of Neurology · doi:10.1002/ana.10279 · Cited by 329
Tofaris, G. K., Garcia Reitböck, P., Humby, T., Lambourne, S. L., O’Connell, M., Ghetti, B., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4965-05.2006 · Cited by 326
The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation
Lotharius, J., & O'Malley, K. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005385200 · Cited by 306
Self-citationParisiadou, L., Xie, C., Cho, H. J., Lin, X., Gu, X.-L., Long, C.-X., Lobbestael, E., Baekelandt, V., Taymans, J.-M., Sun, L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3799-09.2009 · Cited by 306
Incidence and remaining lifetime risk of Parkinson disease in advanced age
Driver, J. A., Logroscino, G., Gaziano, J. M., & Kurth, T. (2009) · Neurology · doi:10.1212/01.wnl.0000341769.50075.bb · Cited by 298
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease
Garcia-Reitböck, P., Anichtchik, O., Bellucci, A., Iovino, M., Ballini, C., Fineberg, E., Ghetti, B., Della Corte, L., Spano, P., Tofaris, G. K., et al. (2010) · Brain · doi:10.1093/brain/awq132 · Cited by 292
Striatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three Questions
Greggio, E., & Cookson, M. R. (2009) · ASN Neuro · doi:10.1042/an20090007 · Cited by 272
Sasaki, Y., Vohra, B. P. S., Lund, F. E., & Milbrandt, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5469-08.2009 · Cited by 243
Braak, H., Sandmann-Keil, D., Gai, W., & Braak, E. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00208-6 · Cited by 242
Finn, J. T., Weil, M., Archer, F., Siman, R., Srinivasan, A., & Raff, M. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01333.2000 · Cited by 242
Choi, W.-S., Kruse, S. E., Palmiter, R. D., & Xia, Z. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807581105 · Cited by 236
Kupsky, W. J., Grimes, M. M., Sweeting, J., Bertsch, R., & Cote, L. J. (1987) · Neurology · doi:10.1212/wnl.37.7.1253 · Cited by 233
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
Dyskinesia after fetal cell transplantation for parkinsonism: A PET study
Ma, Y., Feigin, A., Dhawan, V., Fukuda, M., Shi, Q., Greene, P., Breeze, R., Fahn, S., Freed, C., & Eidelberg, D. (2002) · Annals of Neurology · doi:10.1002/ana.10359 · Cited by 219
α‐Synuclein promoter confers susceptibility to Parkinson's disease
Pals, P., Lincoln, S., Manning, J., Heckman, M., Skipper, L., Hulihan, M., Van den Broeck, M., De Pooter, T., Cras, P., Crook, J., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20268 · Cited by 212
Eberhardt, O., Coelln, R. V., Kügler, S., Lindenau, J., Rathke-Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09126.2000 · Cited by 209
Axonal Degeneration Is Mediated by the Mitochondrial Permeability Transition Pore
Barrientos, S. A., Martinez, N. W., Yoo, S., Jara, J. S., Zamorano, S., Hetz, C., Twiss, J. L., Alvarez, J., & Court, F. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4065-10.2011 · Cited by 207
The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease
Hastings, T. G. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9257-z · Cited by 199 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript cellular processes including axon function (Hastings, 2009).”
BackgroundLiang, C.-L., Wang, T. T., Luby-Phelps, K., & German, D. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.015 · Cited by 185
Why have we failed to achieve neuroprotection in Parkinson's disease?
Olanow, C. W., Kieburtz, K., & Schapira, A. H. V. (2009) · Annals of Neurology · doi:10.1002/ana.21461 · Cited by 183
Choi, W.-S., Palmiter, R. D., & Xia, Z. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009132 · Cited by 183
Herkenham, M., Little, M. D., Bankiewicz, K., Yang, S.-C., Markey, S. P., & Johannessen, J. N. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90180-v · Cited by 180
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease
Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M. J., Kholodilov, N., & Burke, R. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606401103 · Cited by 168
Self-citationDysautonomia in Parkinsonism: a clinicopathological study.
Rajput, A. H., & Rozdilsky, B. (1976) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.39.11.1092 · Cited by 164
Ma, S. Y., Röyttä, M., Rinne, J. O., Collan, Y., & Rinne, U. K. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00100-7 · Cited by 160
Paglini, M. G., Kunda, P. E., Quiroga, S., Kosik, K. S., & Cáceres, A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.443 · Cited by 157
Yahata, N., Yuasa, S., & Araki, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4304-08.2009 · Cited by 154 · cited 3×
“Despite WldS being primarily localized in the nucleus, subcellular localization studies have found substantial amounts of WldS within the mitochondrial matrix where it may enhance ATP synthesis (Yahata et al., 2009), prevent free radical formation (Press and Milbrandt, 2008), and/or maintain mitochondrial membrane pot…”
BackgroundInfluentialWldS requires Nmnat1 enzymatic activity and N16–VCP interactions to suppress Wallerian degeneration
Avery, M. A., Sheehan, A. E., Kerr, K. S., Wang, J., & Freeman, M. R. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200808042 · Cited by 153
What causes the death of dopaminergic neurons in Parkinson’s disease?
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83004-3 · Cited by 151
The Parkinsonian Mimetic, MPP+, Specifically Impairs Mitochondrial Transport in Dopamine Axons
Kim‐Han, J. S., Antenor‐Dorsey, J. A. V., & O’Malley, K. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0711-11.2011 · Cited by 148
Self-citationMorfini, G. A., Pigino, G. F., Opalach, K., Serulle, Y., Moreira, J. E., Sugimori, M., Llinás, R. R., & Brady, S. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611231104 · Cited by 146
Akt Suppresses Retrograde Degeneration of Dopaminergic Axons by Inhibition of Macroautophagy
Cheng, H.-C., Kim, S. R., Oo, T. F., Kareva, T., Yarygina, O., Rzhetskaya, M., Wang, C., During, M. J., Tallóczy, Z., Tanaka, K., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5519-10.2011 · Cited by 145
Self-citationDopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration
Kim, S. R., Chen, X. M., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M. J., Kholodilov, N. G., & Burke, R. E. (2011) · Annals of Neurology · doi:10.1002/ana.22383 · Cited by 145
Self-citationWlds-Mediated Protection of Dopaminergic Fibers in an Animal Model of Parkinson Disease
Sajadi, A., Schneider, B. L., & Aebischer, P. (2004) · Current Biology · doi:10.1016/j.cub.2004.01.053 · Cited by 142 · cited 1×
“WldS also effectively blocks axon degeneration in animal models of PD (Cheng and Burke, 2010, Hasbani and O'Malley, 2006, Sajadi et al., 2004).”
BackgroundNmnat delays axonal degeneration caused by mitochondrial and oxidative stress
Press, C., & Milbrandt, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0525-08.2008 · Cited by 137 · cited 2×
“…subcellular localization studies have found substantial amounts of WldS within the mitochondrial matrix where it may enhance ATP synthesis (Yahata et al., 2009), prevent free radical formation (Press and Milbrandt, 2008), and/or maintain mitochondrial membrane potential (Ikegami and Koike, 2003).”
BackgroundChan, C. S., Gertler, T. S., & Surmeier, D. J. (2010) · Movement Disorders · doi:10.1002/mds.22801 · Cited by 132
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<819::aid-mds1009>3.0.co;2-p · Cited by 131
WldS protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice
Conforti, L., Wilbrey, A. L., Morreale, G., Janečková, L., Beirowski, B., Adalbert, R., Mazzola, F., Stefano, M. D., Hartley, R., Babetto, E., et al. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200807175 · Cited by 130
Cartelli, D., Ronchi, C. L., Maggioni, M. G., Rodighiero, S., Giavini, E., & Cappelletti, G. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06924.x · Cited by 127
Hayley, S. P., Crocker, S. J., Smith, P. D., Shree, T., Jackson-Lewis, V. R., Przedborski, S., Mount, M., Slack, R. S., Anisman, H., & Park, D. S. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4564-03.2004 · Cited by 125
Richardson, J. R., Caudle, W. M., Guillot, T. S., Watson, J. L., Nakamaru‐Ogiso, E., Seo, B. B., Sherer, T., Greenamyre, J. T., Yagi, T., Matsuno‐Yagi, A., et al. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl133 · Cited by 124
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116 · cited 1×
“…the yeast single subunit NADH dehydrogenase gene, Ndl 1, support an obligatory role for Complex I activity in mediating the toxic effects of MPP+ since the yeast gene is able to rescue cells or mice from toxin treatment (Marella et al., 2008, Richardson et al., 2007, Sherer et al., 2003).”
BackgroundInduction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons
Yang, Y., Fukui, K., Koike, T., & Zheng, X. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05914.x · Cited by 113
Ikegami, K., & Koike, T. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.057 · Cited by 102
Serra, P. A., Sciola, L., Delogu, M. R., Spano, A., Monaco, G., MIELE, E., Rocchitta, G., Miele, M., Migheli, R., & Desole, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202099200 · Cited by 96
Meissner, W. G., Prunier, C., Guilloteau, D., Chalon, S., Gross, C. E., & Bézard, E. (2003) · Molecular Neurobiology · doi:10.1385/mn:28:3:209 · Cited by 96
Cappelletti, G., Surrey, T., & Maci, R. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.07.058 · Cited by 94
Mitochondrial dynamics, cell death and the pathogenesis of Parkinson’s disease
Büeler, H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0465-0 · Cited by 94
WldS mice are protected against the Parkinsonian mimetic MPTP
HASBANI, D., & O’Malley, K. L. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.05.017 · Cited by 83
Self-citationRies, V., Silva, R. M., Oo, T. F., Cheng, H., Rzhetskaya, M., Kholodilov, N. G., Flavell, R. A., Kuan, C.-Y., RAKIC, P. T., & Burke, R. E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05713.x · Cited by 82
Self-citationInvited Article: Functional imaging in Parkinson disease
Nandhagopal, R., McKeown, M. J., & Stoessl, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310432.92489.90 · Cited by 77
Yan, L., Findlay, G. M., Jones, R., Procter, J., Cao, Y., & Lamb, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600028200 · Cited by 70
Chen, X., Rzhetskaya, M., Kareva, T., Bland, R., During, M. J., Tank, A. W., Kholodilov, N., & Burke, R. E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2132-07.2008 · Cited by 62
Self-citationEl‐Khodor, B. F., & Burke, R. E. (2002) · The Journal of Comparative Neurology · doi:10.1002/cne.10367 · Cited by 51
Self-citationCheng, H., & Burke, R. E. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06632.x · Cited by 38
Self-citationIseki, E., Kato, M., Marui, W., Uéda, K., & Kosaka, K. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00481-6 · Cited by 38
Hasbani, D. M., Perez, F. A., Palmiter, R. D., & O’Malley, K. L. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0130-05.2005 · Cited by 36
Self-citationLi, L.-H., Qin, H.-Z., Wang, J.-L., Wang, J., Wang, X.-L., & Gao, G.-D. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700221 · Cited by 29
WldS, Nmnats and axon degeneration-progress in the past two decades
Feng, Y., Yan, T., He, Z., & Zhai, Q. (2010) · Protein & Cell · doi:10.1007/s13238-010-0021-2 · Cited by 25
Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals
Mijatovic, J., Piltonen, M., Alberton, P., Männistö, P. T., Saarma, M., & Piepponen, P. T. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.009 · Cited by 23
Muroyama, A., Kobayashi, S., & Mitsumoto, Y. (2010) · Neuroscience Research · doi:10.1016/j.neures.2010.12.009 · Cited by 12
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514
Ashrafi, G., Schlehe, J. S., LaVoie, M. J., & Schwarz, T. L. (2014) · Journal of Cell Biology · doi:10.1083/jcb.201401070 · Cited by 502
“Quality control of axonal mitochondria, however, is of particular interest because axonal degeneration precedes the loss of the soma in neuro degenerative diseases, such as PD (Burke and O’Malley, 2013).”
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · The FEBS Journal · doi:10.1111/febs.14607 · Cited by 444
Metadata
- Authors
- Burke, R. E., & O'Malley, K.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 246
- Pages
- 72-83
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2070049573
- Cited by
- 493
- References
- 123
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.